FrancophonIA/ELRC3.0 huggingface dataset:
English: In the same population, plasma elimination half-life is approximately 2.5 hours, plasma clearance 55 to 80 ml/kg/hr and volume of distribution of approximately 185 to 260 ml/kg.
Maltese: 2.5 sigħat, it-tneħħija mill-plażma 55 sa 80 ml/kg/siegħa u l-volum tad-distribuzzjoni ta' bejn wieħed u ieħor 185 sa 260 ml/kg.
English: Results on the primary endpoint were mainly attributed to the reduction of enzymatic MI occurrence, identified as the occurrence of early elevation of cardiac enzymes after PCI (80 out of 92 MIs in the placebo group vs. 47 out of 56 MIs in the eptifibatide group).
Maltese: Irriżultati tal-punt finali primarju kienu prinċipalment attribwiti għat-tnaqqis ta' l-okkorrenza ta' MI enzimatika, identifikata bħala l-okkorrenza ta' elevazzjoni bikrija ta' enzimi kardijaċi wara PCI (80 minn 92 MIs fil-grupp tal-plaċebo vs.
English: In the eptifibatide arm of the trial, virtually all patients received aspirin (99.7 %), and 98.1 % received a thienopyridine, (clopidogrel in 95.4 % and ticlopidine in 2.7 %).
Maltese: Fil-grupp tal-prova ta' eptifibatide, kważi l-pazjenti kollha rċevew aspirin (99.7 %), u 98.1 % irċevew thienopyridine, (clopidogrel f'95.4
English: − if you have been treated with another medicine of the same type as Eptifibatide Accord.
Maltese: − jekk kont ikkurat b'mediċina oħra ta' l-istess tip ta' Eptifibatide Accord.
English: In patients with moderate renal impairment (creatinine clearance ≥ 30 - < 50 ml/min), an intravenous bolus of 180 microgram/kg should be administered followed by a continuous infusion dose of 1.0 microgram/kg/min for the duration of therapy.
Maltese: F'pazjenti b'indeboliment renali moderat (tneħħija tal-krejatinina ta' ≥ 30 - < 50 ml/min), għandu jingħata bolus fil-vini ta' 180 mikrogramma/kg segwit minn doża ta' infużjoni kontinwa ta' 1.0 mikrogramma/kg/min għat-tul tat-terapija.
English: Cardiac arrest, congestive heart failure, atrial fibrillation, hypotension, and shock, which are commonly reported events from the PURSUIT trial, were events related to the underlying disease.
Maltese: Waqfien tal-qalb, insuffiċjenza konġestiva tal-qalb, fibrillazzjoni atrijali, pressjoni baxxa, u xokk, li huma avvenimenti irrappurtati b'mod komuni fil-prova PURSUIT, kienu avvenimenti relatati mal marda eżistenti minn qabel.
English: MARKETING AUTHORISATION NUMBER(S)
Maltese: NUMRU(/I)
English: − skin rash (such as hives).
Maltese: − raxx fil-ġilda (bħal urtikarja).
English: When followed by a 2.0 microgram/kg/min continuous infusion, this regimen produces a > 80 % inhibition of ADP-induced ex vivo platelet aggregation, at physiologic calcium concentrations, in more than 80 % of patients.
Maltese: Meta segwit minn infużjoni kontinwa ta' 2.0 mikrogrammi/kg/min, dan il-kors jipproduċi impedizzjoni ta' > 80 % ta' laggregazzjoni tal-plejtlits ex vivo kkaġunata minn ADP, f'konċentrazzjonijiet fiżjoloġiċi tal-kalċju,
English: Each ml of solution for injection contains 2 mg of eptifibatide.
Maltese: U KWANTITATTIVA Kull ml ta' soluzzjoni għall-infużjoni fih 2 mg ta' eptifibatide.
English: If either a confirmed platelet decrease to < 100,000/mm3 or acute profound thrombocytopenia is observed, discontinuation of each treatment medication having known or suspected thrombocytopenic effects, including eptifibatide, heparin and clopidogrel, should be considered immediately.
Maltese: Jekk ikun osservat tnaqqis ikkonfermat tal-plejtlits għal < 100,000/mm3 jew tromboċitopenija akuta profonda, għandu jiġi kkunsidrat minnufih il-waqfien ta' kull mediċina li tikkura li għandha jew hemm suspett li għandha effetti tromboċitopeniċi, inkluż eptifibatide, heparin u clopidogrel.
English: This study was a 726-center, 27-country, double-blind, randomised, placebo-controlled study in 10,948 patients presenting with UA or NQMI.
Maltese: Dan l-istudju kien jikkonsisti f'726 ċentru, 27 pajjiż, double-blind, randomised, ikkontrollat bil-plaċebo, u sar fuq 10,948 pazjent li kellhom UA jew NQMI. Il-pazjenti setgħu jkunu rreġistrati biss jekk kellhom iskemija kardijaka waqt li kienu jistrieħu (≥ 10 minuti) flaħħar 24 siegħa u kellhom:
English: Eptifibatide Accord 2 mg/ml solution for injection: 10 ml vial, pack of one vial.
Maltese: Eptifibatide Accord 2 mg/ml soluzzjoni għall-injezzjoni: kunjett ta' 10 ml, pakkett ta' kunjett wieħed.
English: Eptifibatide Accord 2 mg/ml solution for injection
Maltese: Eptifibatide Accord 2 mg/ml soluzzjoni għall-injezzjoni
English: With delayed provisional eptifibatide administration, the event rates were 10 % vs 11.5 % in patients who received reduced dose and standard dose respectively (p=0.61).
Maltese: B'għoti proviżorju ttardjat ta' eptifibatide, ir-rati ta' avvenimenti kienu ta' 10% vs 11.5% f'pazjenti li rċevew doża mnaqqsa u doża standard rispettivament (p = 0.61 ).
English: TIMI major bleeding occurred in 2.7 % of patients who received a reduced dose (1microgram/kg/min) vs 4.2 % of patients who received the standard dose (2 microgram/kg/min) when eptifibatide was administered in the early routine fashion (p=0.36).
Maltese: Fsada maġġuri TIMI seħħet fi 2.7 % talpazjenti li rċevew doża mnaqqsa (1 mikrogramma/kg/min) kontra 4.2 % tal-pazjenti li rċevew doża standard (2 mikrogrammi/kg/min) meta eptifibatide ingħata f'rutina bikrija (p = 0.36).
English: ESPRIT: This was a double-blind, multicentre, randomized, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo nonemergent percutaneous coronary intervention (PCI) with stent implantation.
Maltese: Din kienet prova double-blind, multicentre, randomised, b'parallel-group u kkontrollata bil plaċebo li evalwat is-sigurtà u l-effikaċja ta' terapija b'eptifibatide f'pazjenti li kellhom jagħmlu intervent koronarju perkutanju (PCI) mhux emerġenti b'impjantazzjoni ta' stent.
English: Thrombocytopenia, including acute profound thrombocytopenia, has been observed with eptifibatide administration post-marketing (see section 4.8)
Maltese: B'għoti wara t-tqegħid fis-suq ta' eptifibatide kienet osservata tromboċitopenija, inkluż tromboċitopenija akuta profonda (ara sezzjoni 4.8).
English: Eptifibatide Accord 0.75 mg/ml solution for infusion
Maltese: Eptifibatide Accord 0.75 mg/ml soluzzjoni għall-infużjoni
English: If the patient weighs < 70 kg, a bolus dose of 60 units/kg is recommended, followed by an infusion of 12 units/kg/hr.
Maltese: Jekk il-pazjent jiżen < 70 kg, huwa rrakkomandat li tingħata doża bolus ta' 60 unità/kg, segwita minn infużjoni ta' 12-il unità/kg/hr.
English: Physical and chemical compatibility testing indicate that Eptifibatide Accord may be administered through an intravenous line with atropine sulfate, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, tissue plasminogen activator, or verapamil.
Maltese: .6 Prekawzjonijiet speċjali li għandhom jittieħdu meta jintrema Testijiet fiżiċi u kimiċi dwar il-kompatibilità jindikaw li Eptifibatide Accord jista' jingħata minn linja għal ġol-vini ma' atropine sulfate, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, attivatur ta' plażminoġen fit-tessut, jew verapamil.
English: Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein (GP) IIb/IIIa receptors.
Maltese: fibrinoġen, tal-fattur von Willebrand u ta' ligandi oħra li jeħlu, mar-riċetturi tal-glikoproteini (GP)
English: Each ml of solution for infusion contains 0.75 mg of eptifibatide.
Maltese: U KWANTITATTIVA Kull ml ta' soluzzjoni għall-infużjoni fih 0.75 mg ta' eptifibatide.
English: Platelet inhibition was readily reversed, with a return of platelet function towards baseline (> 50 % platelet aggregation) 4 hours after stopping a continuous infusion of 2.0 microgram/kg/min.
Maltese: L-impedizzjoni tal-plejtlits kienet riversibbli malajr, b'ritorn tal-funzjoni tal-plejtlits lejn il-linja bażi (aggregazzjoni tal-plejtlits ta' > 50 %) 4 sigħat wara li l-infużjoni kontinwa ta' 2.0 mikrogrammi/kg/min twaqqfet.
English: Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.
Maltese: Eptifibatide Accord huwa maħsub għall-prevenzjoni ta' infart mijokardijaku bikri f'adulti li jbatu minn anġina mhux stabbli jew infart mijokardijaku tat-tip tal-mewġa li mhix Q (non-Q-wave), bl aħħar episodju ta' uġigħ tas-sider li seħħ fl-aħħar 24 siegħa u b'bidliet fl-elettrokardjogramm (ECG) u/jew enzimi kardijaċi elevati.
English: Pharmacotherapeutic group: Antithrombotic agent (platelet aggregation inhibitors excl. heparin), ATC code: B01AC16
Maltese: Eptifibatide Accord m'għandux jintuża biex jikkura pazjenti bi: − sensittività eċċessiva għas-sustanza attiva jew għal xi sustanzi mhux attivi elenkati f'sezzjoni
English: If you have kidney disease, the infusion dose may be reduced to 1 microgram/kg/minute.
Maltese: Jekk għandek mard tal-kliewi, d-doża ta' l-infużjoni tista' tiġi mnaqqsa għal 1 mikrogramma/kg/minuta.
English: It is contraindicated in patients with clinically significant hepatic impairment.
Maltese: Huwa kontra-indikat f'pazjenti b'indeboliment tal-fwied ta' sinifikanza klinika.
English: Therefore, it is not recommended to administer eptifibatide in patients who have previously experienced immune mediated thrombocytopenia with GP IIb/IIIa inhibitors, including eptifibatide.
Maltese: Għalhekk, mhux irrakkomandat li eptifibatide jingħata lill-pazjenti li fil-passat kellhom tromboċitopenija medjata mill-immunità kkawżata minn inibituri ta' GP IIb/IIIa, inkluż eptifibatide.
English: Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.
Maltese: Eptifibatide Accord huwa maħsub għall-użu flimkien ma' acetylsalicylic acid u heparin mhux frazzjonat.
English: For a 2.0 microgram/kg/min infusion, mean steady-state plasma eptifibatide concentrations range from 1.5 to 2.2 microgram/ml in patients with coronary artery disease.
Maltese: Għal infużjoni ta' 2.0 mikrogrammi/kg/min, il-konċentrazzjonijiet medji fil-plażma ta' eptifibatide fi stat fiss ivarjaw minn 1.5 sa 2.2 mikrogrammi/ml f'pazjenti b'mard ta' l-arterja koronarja.
English: Frequencies are defined as very common (≥ 1/10); common (≥ 1/100 to< 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to
Maltese: Il-frekwenzi huma definiti bħala komuni ħafna (≥1/10); komuni (≥ 1/100 sa < 1/10); mhux komuni (≥ 1/1,000 sa <
English: In patients with moderate to severe renal insufficiency (creatinine clearance < 50 ml/min), the clearance of eptifibatide is reduced by approximately 50 % and steady-state plasma levels are approximately doubled.
Maltese: F'pazjenti b'insuffiċjenza moderata sa severa tal-kliewi (tneħħija tal-krejatinina ta' < 50 ml/min), it-tneħħija ta' eptifibatide tonqos b'madwar 50% u l-livelli fil-plażma fi stat fiss ftit jew wisq jirduppjaw.
English: Eptifibatide Accord 0.75 mg/ml: Each ml of solution for infusion contains 0.75 mg of eptifibatide.
Maltese: Eptifibatide Accord 0.75 mg/ml: Kull ml ta' soluzzjoni għall-infużjoni fih 0.75 mg ta'
English: What is in this leaflet:
Maltese: Detentur tal-Awtorizzazzjoni għat-tqegħid fis-Suq:
English: GUSTO moderate or severe/life threatening bleeding occurred significantly more often with early routine eptifibatide (7.4 % vs. 5.0 % in delayed provisional eptifibatide group; p <0.001).
Maltese: Fsada GUSTO moderata jew qawwija/ta' periklu għall-ħajja seħħet b'mod sinifikanti aktar ta' spiss b'għoti bikri ta' eptifibatide bħala rutina (7.4% vs. 5.0% fil-grupp ta' għoti provviżorju mdewwem ta' eptifibatide;
English: Eptifibatide Accord 0.75 mg/ml solution for infusion eptifibatide
Maltese: Eptifibatide Accord 0.75 mg/ml, soluzzjoni għall-infużjoni
English: The incidence of severe or life threatening bleeding events with eptifibatide was 1.9 % compared to 1.1 % with placebo.
Maltese: L-inċidenza ta' avvenimenti ta' fsada severa jew ta' periklu għall-ħajja b'eptifibatide kienet ta' 1.9% meta mqabbel ma' 1.1% bil-plaċebo.
English: - if you have or have had bleeding problems.
Maltese: − jekk għandek jew kellek problemi ta' fsada.
English: Eptifibatide -treated patients who had a prothrombin time (PT) > 14.5 seconds and received warfarin concomitantly did not appear to be at an increased risk of bleeding.
Maltese: > 14.5 sekondi u li rċevew ukoll warfarin, ma dehrux li kienu f'riskju miżjud ta' fsada.
English: Eptifibatide Accord 0.75 mg/ml: The clear, colourless solution is contained in a 100 ml glass vial, which is closed with a butyl rubber stopper and sealed with a flip-off aluminium seal.
Maltese: Eptifibatide Accord 0.75 mg/ml: Is-soluzzjoni ċara u bla kulur hija disponibbli ġewwa kunjett talħġieġ ta' 100 ml, li huwa magħluq b'tapp tal-lastku butyl u ssiġillat b'siġill li jista' jinqala' ta' l aluminju.
English: Very rarely, bleeding has become severe and even fatal.
Maltese: Il-fsada rari ħafna ssir serja u anki fatali.
English: Similar results were also obtained for the 2 secondary endpoints assessed at 30 days: a triple composite of death, MI and UTVR, and the more robust combination of death and MI.
Maltese: Riżultati simili kienu miksuba għaż-żewġ punti finali sekondarji assessjati fit-30 jum: kompost triplu ta' mewt, MI u UTVR, u t-taħlita iktar robusta ta' mewt u MI.
English: Package leaflet: Information for the patient Eptifibatide Accord 0.75 mg/ml solution for infusion eptifibatide
Maltese: Informazzjoni għall-utent Eptifibatide Accord 0.75 mg/ml soluzzjoni għall-infużjoni eptifibatide
English: How to use Eptifibatide Accord
Maltese: Tużax Eptifibatide Accord:
English: Blood and Lymphatic System Disorder
Maltese: Disturbi tad-Demm u tas-Sistema Limfatika
English: With delayed provisional eptifibatide administration, the TIMI major events were 1.4 % vs 2.0 % in patients who received reduced dose and standard dose respectively (p=0.54).There were no notable differences observed with GUSTO severe bleeding rates.
Maltese: B'għoti proviżorju ttardjat ta' eptifibatide, l-avvenimenti maġġuri TIMI kienu ta' 1.4 % vs 2.0% f'pazjenti li rċevew doża mnaqqsa u doża standard rispettivament (p = 0.54).
English: Shock, hypotension, phlebitis.
Maltese: Pressjoni baxxa, xokk, flebite.
English: The clinical relevance of such enzymatic MIs is still controversial.
Maltese: Ir-rilevanza klinika ta' MIs enzmatiċi bħal dawn għadha kontroversjali.
English: Measurements of ADP-induced ex vivo platelet aggregation at physiologic calcium concentrations (Dphenylalanyl-L-prolyl-L-arginine chloromethyl ketone anticoagulant) in patients presenting with unstable angina and Non Q-Wave Myocardial Infarction showed a concentration-dependent inhibition with an IC50 (50 % inhibitory concentration) of approximately 550 ng/ml and an IC80 (80 % inhibitory concentration) of approximately 1,100 ng/ml.
Maltese: b'IC50 (konċentrazzjoni li timpedixxi 50 %) ta' madwar 550 ng/ml u IC80 (konċentrazzjoni li timpedixxi 80 %) ta' madwar 1,100 ng/ml.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Maltese: Informazzjoni dettaljata dwar dan il-prodott tinsab fuq is-sit elettroniku ta' l-Aġenzija Ewropea dwar il-Mediċini http://www.ema.europa.eu/.
English: Eptifibatide Accord is given into the vein by direct injection followed by an infusion (drip solution).
Maltese: Eptifibatide Accord jingħata fill-vini b'injezzjoni diretta segwita minn infużjoni (soluzzjoni likwida bid dripp).
English: The primary endpoint analysis [quadruple composite of death, MI, urgent target vessel revascularisation (UTVR) and thrombolytic bail-out (TBO) at 48 hours] showed a 37 % relative and 3.9 % absolute reduction in the eptifibatide group (6.6 % events versus 10.5 %, p= 0.0015).
Maltese: u tnaqqis assolut ta' 3.9 % fil-grupp ta' eptifibatide (6.6 % avvenimenti kontra 10.5 %, p = 0.0015).
English: Minor bleeding was defined in the PURSUIT trial as spontaneous gross haematuria, spontaneous haematemesis, observed blood loss with a haemoglobin decrease of more than 3 g/dl, or a haemoglobin decrease of more than 4 g/dl in the absence of an observed bleeding site.
Maltese: Fil-prova PURSUIT, fsada minuri kienet imfissra bħala ematurja spontanja qawwija, rimettar spontanju ta' demm, telf ta' demm osservat bi tnaqqis fl-emoglobina ta' iktar minn 3 g/dl, jew tnaqqis fl-emoglobina ta' iktar minn 4 g/dl mingħajr osservazzjoni ta' sit ta' fsada.
English: Before infusion of Eptifibatide Accord, the following laboratory tests are recommended to identify preexisting haemostatic abnormalities: prothrombin time (PT) and aPTT, serum creatinine, platelet count, haemoglobin and haematocrit levels.
Maltese: Is-sorveljanza ta' valuri tal-laboratorju Qabel l-infużjoni ta' Eptifibatide Accord, dawn it-testijiet tal-laboratorju li ġejjin huma rrakkomandati biex ikunu identifikati anormalitajiet emostatiċi li kienu jeżistu minn qabel: ħin ta' prothrombin (PT) u aPTT, krejatinina fis-serum, għadd tal-plejtlits, u livelli ta' l-emoglobina u ta' l-ematokrit.
English: Since either repeat exposure with any GP IIb/IIIa ligand-mimetic agent (like abciximab or eptifibatide) or first-time exposure to a GP IIb/IIIa inhibitor may be associated with immune-mediated thrombocytopenic responses, monitoring is required, i.e. platelet counts should be monitored prior to treatment, within 6 hours of administration, and at least once daily thereafter while on therapy and immediately at clinical signs of unexpected bleeding tendency.
Maltese: Peress li esponiment ripetut għal kwalunkwe sustanza li timmimika l-ligand GP IIb/IIIa (bħal abciximab jew eptifibatide) jew espożizzjoni għall-ewwel darba għall-inibitur ta' GP IIb/IIIa jista' jkun assoċjat ma' risponsi tromboċitopeniċi medjati mill-immunità, sorveljanza hija meħtieġa, i.e. lgħadd tal-plejtlits għandhom jiġu ssorveljati qabel il-kura, fi żmien 6 sigħat mill-għoti, u wara dan mill-inqas darba kuljum waqt it-terapija u minnufih meta jkun hemm sinjali kliniċi ta' tendenza ta'
English: In an acute myocardial infarction study involving 181 patients, eptifibatide (in regimens up to a bolus injection of 180 microgram/kg, followed by an infusion up to 2 microgram/kg/min for up to 72 hours) was administered concomitantly with streptokinase (1.5 million units over 60 minutes).
Maltese: 2 mikrogrammi/kg/min sa 72 siegħa) kien mogħti flimkien ma' streptokinase (1.5 miljun unità matul perijodu ta' 60 minuta).
English: use.
Maltese: INDIVIDWALI.
English: If percutaneous coronary intervention (PCI) is performed during Eptifibatide Accord therapy, the intravenous solution may be continued for up to 96 hours.
Maltese: Jekk isir intervent koronarju perkutanju (PCI) matul it-terapija b'Eptifibatide Accord, is-soluzzjoni fil vini għandha mnejn titkompla sa 96 siegħa.
English: Skin and subcutaneous tissue disorders
Maltese: Eptifibatideu sustanzi trombolitiċi
English: INSTRUCTIONS ON USE
Maltese: Prova PURSUIT
English: Bleeding (major and minor bleeding including femoral artery access, CABG-related, gastrointestinal, genitourinary, retroperitoneal, intracranial, haematemesis, haematuria, oral/oropharyngeal, haemoglobin/haematocrit decreased and other).
Maltese: CABG, gastro-intestinali, genitourinarja, retroperitonali, fil-kranju, rimettar ta'
English: In patients with severe renal impairment (creatinine clearance < 30 ml/min) administered 1microgram/kg/min , 80 % inhibition was achieved in more than 80 % of patients at 24 hours.
Maltese: F'pazjenti b'indeboliment renali sever (tneħħija talkrejatinina < 30 mL/min) li ngħataw 1 ug/kg/min, inkisbet inibizzjoni ta' 80% f'aktar minn 80% tal pazjenti fi żmien 24 siegħa.
English: Because Eptifibatide Accord inhibits platelet aggregation, caution must be employed when it is used with other medicinal products that affect haemostasis, including ticlopidine, clopidogrel, thrombolytics, oral anticoagulants, dextran solutions, adenosine, sulfinpyrazone, prostacyclin, nonsteroidal anti-inflammatory agents, or dypyridamole (see section 4.5).
Maltese: Peress li Eptifibatide Accord jimpedixxi l-aggregazzjoni tal-plejtlits, wieħed għandu joqgħod attent meta jkun użat ma' prodotti mediċinali li jaffettwaw l-emostasi, li jinkludu ticlopidine, clopidogrel, trombolitiċi, mediċini li jittieħdu mill-ħalq kontra il-koagulazzjoni, soluzzjonijiet ta' dextran,
English: Teratology studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits at total daily doses of up to 36 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis).
Maltese: kuljum sa 72 mg/kg/kuljum (madwar 4 darbiet aktar mid-doża massima ta' kuljum rrakkomandata għall-bnedmin fuq bażi ta' l-erja tas-superfiċje tal-ġisem) u fi fniek tqal b'dożi totali ta' kuljum sa
English: < 1/1000); very rare (< 1/10,000); not known (cannot be estimated from available data).
Maltese: < 1/100); rari (≥ 1/10,000 sa < 1/1,000); rari ħafna (< 1/10,000); mhux magħrufa (ma tistax tiġi stmata mid-dejta disponibbli).
English: If PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours.
Maltese: eptifibatide tkompliet għal 24 siegħa wara l-proċedura, u dan jippermetti tul ta' l-infużjoni sa 96 siegħa.
English: How to store Eptifibatide Accord
Maltese: X'fih Eptifibatide Accord
English: You must also be given doses of aspirin and heparin (if not contraindicated in your case).
Maltese: Int għandek tingħata wkoll dożi ta' aspirina u heparin (jekk dawn mhux kontra-indikati fil-każ tiegħek).
English: Eptifibatide Accord must not be used to treat patients with: - hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - evidence of gastrointestinal bleeding, gross genitourinary bleeding or other active abnormal bleeding within the previous 30 days of treatment - history of stroke within 30 days or any history of haemorrhagic stroke - known history of intracranial disease (neoplasm, arteriovenous malformation, aneurysm) - major surgery or severe trauma within past 6 weeks - a history of bleeding diathesis - thrombocytopenia (< 100,000 cells/mm3) - prothrombin time > 1.2 times control, or International Normalized Ratio (INR) ≥ 2.0 - severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure
Maltese: − jekk inti allerġiku għal eptifibatide jew għal xi sustanza oħra ta' din il-mediċina (elenkati fis sezzjoni 6). − jekk dan l-aħħar kellek fsada mill-istonku, mill-imsaren, mill-bużżieqa ta' l-awrina jew minn organi oħra, per eżempju jekk rajt xi demm anormali fil-ħmieġ jew fl-awrina tiegħek (ħlief għal fsada mestrwali) fl-aħħar 30 jum.
English: EARLY-ACS trial
Maltese: B01AC16
English: There is limited therapeutic experience with eptifibatide in patients for whom thrombolytic therapy is generally indicated (e.g. acute transmural myocardial infarction with new pathological Q-waves or elevated ST-segments or left bundle branch block in the ECG).
Maltese: Hemm esperjenza terapewtika limitata dwar l-użu ta' eptifibatide f'pazjenti li ġeneralment għandhom bżonn terapija trombolitika (eż., infart mijokardijaku transmurali akut b'mewġiet patoloġiċi tat-tip Q
English: Eptifibatide Accord 2 mg/ml: The clear, colourless solution is contained in a 10 ml glass vial, which is closed with a butyl rubber stopper and sealed with a flip-off aluminium seal.
Maltese: Eptifibatide Accord 2 mg/ml: Is-soluzzjoni ċara u bla kulur hija disponibbli ġewwa kunjett tal-ħġieġ ta' 10 ml, li huwa magħluq b'tapp tal-lastku butyl u ssiġillat b'siġill li jista' jinfetaħ ta' l-aluminju.